Chronic Kidney Disease – Landscape & Forecast – Disease Landscape & Forecast

The chronic kidney disease (CKD) therapy market comprises a wide variety of antihypertensive agents and SGLT-2 inhibitors to delay the progression of kidney damage. RAAS inhibitors are the standard of care, and SGLT-2 inhibitors (e.g., AstraZeneca’s Farxiga, Eli Lilly’s Jardiance) are emerging as the next standard-of-care therapy. Indeed, this drug class’s patient share in CKD is growing rapidly. In 2021, Bayer’s Kerendia, a mineralocorticoid receptor antagonist, received approval for the treatment of diabetic kidney disease, and clinical trials are investigating the drug’s effectiveness in nondiabetic CKD. Despite the availability of medications that can delay the progression of CKD, no therapy can halt or reverse its progression, leaving significant unmet need in CKD treatment.

Questions answered

• Does the inclusion of cardiovascular endpoints in clinical trials of CKD therapies confer a competitive advantage?
• What are the drivers and constraints in the CKD therapy market, and how will the market evolve through 2033?
• What do key opinion leaders consider the advantages and disadvantages of current and emerging therapies?
• What are the greatest unmet needs in the treatment of CKD? Which drugs in development will fulfill these unmet needs?
• What market access and reimbursement challenges will the emerging CKD therapies face? How will these challenges influence their uptake?

Geography: United States, France, Germany, Italy, Spain, United Kingdom, and Japan

Primary research: 20 country-specific interviews with thought-leading nephrologists. Supported by survey data collected for this and other Clarivate research.

Epidemiology: Diagnosed prevalence of CKD by country and stage of disease.

Forecast: 10-year, annualized, drug-level sales and patient share of key CKD therapies through 2033, segmented by brands / generics and epidemiological subpopulations.

Drug treatments: Coverage of key current and emerging therapies.

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.